These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 9358335)

  • 1. A logistic dose-ranging method for phase I clinical investigations trials.
    Murphy JR; Hall DL
    J Biopharm Stat; 1997 Nov; 7(4):635-47. PubMed ID: 9358335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A two-stage dose selection strategy in phase I trials with wide dose ranges.
    Wang O; Faries DE
    J Biopharm Stat; 2000 Aug; 10(3):319-33. PubMed ID: 10959914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Designing dose-escalation trials with late-onset toxicities using the time-to-event continual reassessment method.
    Normolle D; Lawrence T
    J Clin Oncol; 2006 Sep; 24(27):4426-33. PubMed ID: 16983110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. np1: a computer program for dose escalation strategies in phase I clinical trials.
    Kramar A; Houédé N; Paoletti X
    Comput Methods Programs Biomed; 2007 Oct; 88(1):8-17. PubMed ID: 17719124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved designs for dose escalation studies using pharmacokinetic measurements.
    Piantadosi S; Liu G
    Stat Med; 1996 Aug; 15(15):1605-18. PubMed ID: 8858785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I (or phase II) dose-ranging clinical trials: proposal of a two-stage Bayesian design.
    Zohar S; Chevret S
    J Biopharm Stat; 2003 Feb; 13(1):87-101. PubMed ID: 12635905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of model choices for the Continual Reassessment Method in phase I cancer trials.
    Paoletti X; Kramar A
    Stat Med; 2009 Oct; 28(24):3012-28. PubMed ID: 19672839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Three-dose-cohort designs in cancer phase I trials.
    Huang B; Chappell R
    Stat Med; 2008 May; 27(12):2070-93. PubMed ID: 17764082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterogeneity in phase I clinical trials: prior elicitation and computation using the continual reassessment method.
    Legedza AT; Ibrahim JG
    Stat Med; 2001 Mar; 20(6):867-82. PubMed ID: 11252009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-finding study of ibuprofen in patent ductus arteriosus using the continual reassessment method.
    Desfrere L; Zohar S; Morville P; Brunhes A; Chevret S; Pons G; Moriette G; Rey E; Treluyer JM
    J Clin Pharm Ther; 2005 Apr; 30(2):121-32. PubMed ID: 15811164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-escalation designs in oncology: ADEPT and the CRM.
    Shu J; O'Quigley J
    Stat Med; 2008 Nov; 27(26):5345-53; discussion 5354-5. PubMed ID: 18752259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adaptive designs for dose-finding in non-cancer phase II trials: influence of early unexpected outcomes.
    Resche-Rigon M; Zohar S; Chevret S
    Clin Trials; 2008; 5(6):595-606. PubMed ID: 19029208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of the continual reassessment method to a phase I dose-finding trial in Japanese patients: East meets West.
    Morita S
    Stat Med; 2011 Jul; 30(17):2090-7. PubMed ID: 21500239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continual reassessment method: a likelihood approach.
    O'Quigley J; Shen LZ
    Biometrics; 1996 Jun; 52(2):673-84. PubMed ID: 8672707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitivity of dose-finding studies to observation errors.
    Zohar S; O'Quigley J
    Contemp Clin Trials; 2009 Nov; 30(6):523-30. PubMed ID: 19580886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two-sample continual reassessment method.
    O'Quigley J; Shen LZ; Gamst A
    J Biopharm Stat; 1999 Mar; 9(1):17-44. PubMed ID: 10091908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient specific dosing in a cancer phase I clinical trial.
    Babb JS; Rogatko A
    Stat Med; 2001 Jul; 20(14):2079-90. PubMed ID: 11439422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The continual reassessment method for multiple toxicity grades: a Bayesian quasi-likelihood approach.
    Yuan Z; Chappell R; Bailey H
    Biometrics; 2007 Mar; 63(1):173-9. PubMed ID: 17447942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A hybrid Bayesian adaptive design for dose response trials.
    Chang M; Chow SC
    J Biopharm Stat; 2005; 15(4):677-91. PubMed ID: 16022172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal phase I dose-escalation trial designs in oncology--a simulation study.
    Gerke O; Siedentop H
    Stat Med; 2008 Nov; 27(26):5329-44. PubMed ID: 17849502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.